{"id":"nct:NCT06712316","kind":"trial","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)","authors":["BioNTech SE"],"author_count":1,"year":2024,"published":"2024-12-02","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06712316","source_url":"https://clinicaltrials.gov/study/NCT06712316","archive_url":"https://space-kitty.com/papers/nct:NCT06712316","updated":"2026-10-15","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Non-small Cell Lung Cancer"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE2, PHASE3","study_type":"INTERVENTIONAL","enrollment":1580,"sponsor":"BioNTech SE","conditions":["Non-small Cell Lung Cancer"],"interventions":["DRUG: Pumitamig","DRUG: Pembrolizumab","DRUG: Carboplatin","DRUG: Pemetrexed","DRUG: Paclitaxel"],"start_date":"2025-01-07","start_date_type":"ACTUAL","primary_completion_date":"2029-01-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}